Low-Dose Losartan Therapy Reduces Proteinuria in Normotensive Patients with Immunoglobulin A Nephropathy

Abstract

The present study was designed to assess the antiproteinuric effects of a low dose of an angiotensin IIreceptor blocker, losartan, in normotensive patients with immunoglobulin A (IgA) nephropathy. We per-

Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function

“…Previous prospective and randomized trials have indicated that ACEIs [10][11][12] and ARBs [12][13][14][15][16] exert beneficial effects in IgAN patients by reducing urinary protein excretion and improving renal survival rate. Furthermore, trials have shown that a combination therapy with an ACEI plus an ARB may be superior to monotherapy with an ACEI or ARB for reducing urinary protein excretion, lowering blood pressure, and slowing the progression of renal dysfunction [17][18][19][20].…”

Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: A meta-analysis of randomized controlled trials

“…It means that ARBs therapy has an antiproterinuric effect in a blood pressuredependent way in hypertensive 35 or normotensive patients with diabetic nephropathy. Other individual trials [17][18][19][20][21]23,24 included in this meta-analysis also have shown that the reduction of urinary protein excretion appears to be independent of the reduction of blood pressure in normotensive patients. However, this meta-analysis found that ARBs therapy was associated with significant decreases in SBP and DBP.…”

“…A total of eight RCTs [17][18][19][20][21][22][23][24] with 866 patients were identified for inclusion from 232 potentially relevant publications ( Figure 1). Table 1 summarizes the baseline characteristics and study quality of the included trials.…”

“…Because of the fact that the mean baseline blood pressures appeared to be 135.9/78.8 mmHg for the losartan group and 138.3/80.3 mmHg for the placebo group, the authors mentioned that the study sample could be considered normotensive. In addition, three trials 17,18,20 did not mention exclusion of patients previously treated with antihypertensive agents. Second, in order to evaluate the antiproteinuric effect of ARBs, we combined the different stages of nephropathy (early and overt nephropathy) and obtained the pooled estimate, which might induce clinical heterogeneity in this study.…”

Polycythemia Vera Associated with IgA Nephropathy: A Case Report

“…Hemen hemen bütün çalışmalar anjıotensin dönüştürücü enzim inhibitörü (ACE inh.) ve anjiotensin reseptör blokörlerinin proteinüriyi ve böbrek yetmezliğini azalttığını göstermektedir (18)(19)(20). Hastamıza 1 mg/kg günden prednisolon tedavisi başlandı ve izleminde böbrek fonksiyon testleri 5 gün içerisinde normal değerlere ve proteinürisi 1 gr/gün'ün altına geriledi.…”